However, it has also been reported that an increase in anti-PF4/heparin antibody levels does not increase the incidence of thromboembolic events [8], [21] and the anti-PF4/heparin antibody had no effect on the overall mortality or cardiovascular events in the absence of thrombocytopenia[10]. This evidence concerns the gene PF4 and Thrombocytopenia.